Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001610618-25-000032
Filing Date
2025-04-15
Accepted
2025-04-15 17:27:12
Documents
19
Period of Report
2025-06-18

Document Format Files

Seq Description Document Type Size
1 PRELIMINARY PROXY STATEMENT cdtx-20250415.htm   iXBRL PRE 14A 987475
3 GRAPHIC cdtx-20250415_g1.jpg GRAPHIC 46741
4 GRAPHIC cdtx-20250415_g2.jpg GRAPHIC 71708
5 GRAPHIC cdtx-20250415_g3.jpg GRAPHIC 72011
6 GRAPHIC cdtx-20250415_g4.jpg GRAPHIC 2323854
7 GRAPHIC cdtx-20250415_g5.jpg GRAPHIC 1789514
  Complete submission text file 0001610618-25-000032.txt   10940051

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cdtx-20250415.xsd EX-101.SCH 912
21 EXTRACTED XBRL INSTANCE DOCUMENT cdtx-20250415_htm.xml XML 87729
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-36912 | Film No.: 25840678
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)